Diagnosing a gastrointestinal stromal tumor can be challenging because many of these tumors cause no symptoms at first, often being discovered by chance during tests for other conditions. Understanding when to seek evaluation and what diagnostic steps doctors use to identify these rare cancers is essential for early detection and appropriate treatment.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing persistent or unusual digestive symptoms should consider seeking medical evaluation. Gastrointestinal stromal tumors, commonly called GISTs, are rare cancers that develop in the walls of the digestive tract, most often in the stomach or small intestine. Because these tumors can grow slowly without causing noticeable problems, many people only discover they have a GIST when symptoms finally appear or when the tumor is found accidentally during imaging or procedures for unrelated health issues.^[1]

You should talk to your doctor if you notice blood in your stool or vomit. This is one of the most common signs of a GIST. The blood might appear bright red, or it could be very dark, almost black, which indicates the blood has been partially digested as it moved through the digestive system. Other warning signs include persistent pain or discomfort in your abdomen, feeling unusually tired all the time, trouble swallowing, feeling full after eating only a small amount of food, or losing weight without trying.^[2][9]

It’s important to understand that these symptoms can be caused by many conditions other than cancer. However, if you experience any of these problems, especially if they persist or worsen, you should not ignore them. Early evaluation gives your doctor the best chance to identify the problem and start appropriate treatment if needed.^[1]

Certain people have a higher risk of developing GISTs. If you are over 50 years old, you fall into the age group where these tumors occur most commonly. Additionally, if you have certain rare genetic syndromes—which are sets of symptoms or conditions caused by abnormal genes—you may be at increased risk. These syndromes include neurofibromatosis type 1, Carney-Stratakis syndrome, and familial GIST syndrome. People with these conditions should discuss appropriate monitoring strategies with their healthcare providers.^[8][9]

Classic Diagnostic Methods

When a doctor suspects you might have a gastrointestinal stromal tumor, several tests and procedures can help confirm the diagnosis and determine the characteristics of the tumor. The diagnostic process typically begins with a thorough medical history and physical examination. Your doctor will ask about your symptoms, how long you’ve had them, and whether you have any known risk factors for GIST. During the physical exam, the doctor will carefully examine your abdomen to check for any masses or other signs of a tumor.^[10]

Imaging Tests

Imaging tests create pictures of the inside of your body and are crucial for finding tumors and assessing their size and location. Not everyone needs every type of imaging test; your doctor will decide which ones are most appropriate for your situation.^[12]

Computed tomography scans, or CT scans, use X-rays and computer technology to create detailed cross-sectional images of your body. These scans are commonly used to locate GISTs and determine whether the tumor has spread to other organs, particularly the liver, which is a common site of GIST spread. A CT scan of your abdomen and pelvis provides important information about the tumor’s size and its relationship to surrounding structures.^[9][10]

Magnetic resonance imaging, known as MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues in your body. MRI scans can be particularly helpful in certain situations, such as when doctors need more detailed information about a tumor’s characteristics or its relationship to nearby blood vessels and organs.^[12]

Positron emission tomography, or PET scans, involve injecting a small amount of radioactive sugar into your bloodstream. Cancer cells, which typically use more energy than normal cells, absorb more of this sugar and appear as bright spots on the scan. PET scans can help identify whether a GIST has spread to distant parts of the body. Sometimes, PET scans are combined with CT scans to provide both anatomical and functional information in a single test.^[9][12]

Ultrasound uses sound waves to create images of internal organs. While a regular abdominal ultrasound may be performed, a specialized technique called endoscopic ultrasound (EUS) is particularly valuable for evaluating GISTs. During EUS, a thin, flexible tube with an ultrasound probe on its tip is passed through your mouth and into your digestive tract. This allows the probe to get very close to the tumor, providing highly detailed images that show the tumor’s size, which layer of the digestive tract wall it originated from, and its relationship to nearby structures.^[12][13]

Endoscopy

Upper endoscopy, also called esophagogastroduodenoscopy or EGD, involves passing a long, thin tube with a light and camera on the end through your mouth and down your throat. This procedure allows your doctor to directly visualize the inside of your esophagus, stomach, and the first part of your small intestine. If a tumor is visible from inside the digestive tract, the doctor can see it and assess its appearance.^[2][12]

However, many GISTs grow within the wall of the digestive tract rather than protruding into the hollow space inside. This means they may not be easily visible during a standard endoscopy. That’s why endoscopic ultrasound is often more helpful, as it can detect tumors within the wall that wouldn’t be seen with the camera alone.^[13]

Biopsy

A biopsy involves removing a small sample of tissue from the tumor so it can be examined under a microscope in a laboratory. This is the only definitive way to confirm that a tumor is a GIST and not some other type of growth. There are several ways to obtain a biopsy sample.^[12]

Fine-needle aspiration biopsy is often performed during endoscopic ultrasound. After the ultrasound probe locates the tumor, a thin, hollow needle is advanced through the wall of the digestive tract into the tumor. The needle collects small amounts of cells and tissue, which are then sent to the pathology lab for analysis. This technique allows doctors to sample the tumor without making any incisions in your skin.^[12][13]

Sometimes the needle cannot collect enough cells, or the results are unclear. In such cases, you might need a surgical biopsy, where a surgeon removes a larger piece of tissue for examination. This might be done using minimally invasive techniques with small incisions, or it might require a more extensive operation depending on the tumor’s location and size.^[12]

Laboratory Tests

Once the biopsy sample reaches the laboratory, specialists called pathologists examine the cells under a microscope to determine whether they are cancer cells. For GISTs, pathologists look for specific characteristics. They check whether the cells are positive for certain proteins, particularly KIT (CD117), which is found in the vast majority of GISTs. Another protein called DOG1 (discovered on gastrointestinal stromal tumor 1) is also commonly tested and is generally positive in GISTs.^[5][13]

Molecular genetic testing is a crucial part of diagnosing and characterizing a GIST. This testing looks for specific changes, called mutations, in the genes of the tumor cells. About 75 to 80 percent of GISTs have a mutation in the KIT gene, and another 5 to 10 percent have a mutation in a gene called PDGFRA. Less commonly, mutations in genes such as SDHA, SDHB, SDHC, or SDHD are found. Identifying which mutation is present is extremely important because different mutations respond differently to various treatments.^[8][10]

For example, GISTs with certain KIT mutations tend to respond very well to a medication called imatinib, while those with specific PDGFRA mutations, particularly one called D842V, are typically resistant to this drug. Knowing the mutation status helps your doctor choose the most effective treatment for your specific tumor.^[19]

Risk Assessment

After diagnosing a GIST, doctors assess the risk of the disease returning after treatment or spreading to other parts of the body. This risk assessment considers several factors: the size of the tumor, its location in the digestive tract, and the mitotic rate. Based on these factors, GISTs are classified into risk categories such as very low risk, low risk, intermediate risk, or high risk. This classification helps guide treatment decisions and follow-up planning.^[7][13]

Blood tests are also performed to check your overall health and how well your organs are functioning. While there is no specific blood test that diagnoses GIST, routine blood work can detect problems such as anemia—a low red blood cell count—which may result from bleeding caused by the tumor. Blood tests also provide baseline information about your liver and kidney function, which is important for planning treatment.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments or combinations of treatments to find better ways to help people with cancer. If you are considering participating in a clinical trial for GIST, you will undergo specific diagnostic tests to determine whether you meet the eligibility criteria for the study. These criteria are carefully designed to ensure that the trial can safely test the new treatment and provide meaningful results.^[9]

Most clinical trials for GIST require confirmation that you actually have a GIST. This means you must have had a biopsy with tissue examined by a pathologist who confirmed the diagnosis. The pathology report should document that the tumor cells tested positive for KIT or DOG1, which are the characteristic markers of GIST.^[13]

Molecular genetic testing is frequently required for clinical trial enrollment. The trial may be specifically testing a treatment designed for tumors with particular gene mutations. For instance, a trial might only accept patients whose GISTs have a mutation in exon 11 of the KIT gene, or it might exclude patients with the PDGFRA D842V mutation. Your tumor tissue will be tested to determine its mutation status, and this information will determine whether you are eligible for specific trials.^[19]

Imaging tests such as CT scans, MRI scans, or PET scans are standard requirements for clinical trial participation. These tests establish the extent of your disease at the beginning of the study—what doctors call the baseline. The scans document the size and location of all visible tumors. During the trial, you will have repeat imaging at specified intervals, allowing researchers to see whether the treatment is shrinking the tumors, keeping them stable, or failing to control their growth.^[11]

Laboratory tests are also part of the screening process for clinical trials. Blood tests check your blood cell counts, kidney function, and liver function. Clinical trials typically require that these values fall within certain acceptable ranges, ensuring that you are healthy enough to tolerate the experimental treatment and that any side effects can be safely monitored. Some trials may also require specific blood tests related to the treatment being studied.^[9]

Your performance status—a measure of how well you can carry out daily activities—is often assessed. Doctors use standardized scales to rate your level of function. Clinical trials usually require that participants have a good performance status, meaning they are able to care for themselves and are active for at least part of the day. This helps ensure that participants are healthy enough to complete the trial and that researchers can accurately assess the effects of the treatment.^[11]

The stage of your disease is also important for trial eligibility. Some trials are designed for people with early-stage, localized GISTs that can be surgically removed, while others focus on advanced or metastatic disease—cancer that has spread to distant parts of the body. Still other trials may specifically recruit patients whose cancer has not responded to standard treatments, known as refractory disease.^[9][11]

Documentation of previous treatments is typically required. The trial investigators need to know exactly what therapies you have received in the past, how long you took each treatment, and how your cancer responded. Many trials for advanced GIST are designed for patients who have already tried several standard treatments. For example, a trial might require that participants have previously received treatment with specific medications such as imatinib or sunitinib.^[11]

If you are interested in participating in a clinical trial, discuss this option with your oncologist. Your doctor can help identify trials that might be appropriate for your situation and can refer you to the institutions conducting the studies. The diagnostic tests you have already undergone as part of your standard care may be sufficient for trial eligibility, or you may need additional testing. The research team will review all your medical records and test results to determine whether you meet the criteria for participation.^[9]